Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Keywords

Medicine, Rosiglitazone, Myocardial infarction, Cardiology, Internal medicine

References

• Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study*Peter N. Weissman, B. J. Goldstein, J Rosenstock — 2005
• Secondary Prevention of Macro Vascular Events in Patients With Type II Diabetes in the PROactive Study (PROspective Pioglitazone Clinical Trial and Macro Vascular Events): A Randomised Controlled TrialJ A Dormandy, B Charbonnel, D.J.A. Eckland — 2006
• Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.JP Riveline, N Danchin, François Ledru — 2003
• Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetesThomas Jones, Maureen C. Sautter, Luc F. Van Gaal — 2003
• The Clinical Significance of PPAR Gamma Agonism.Ian W. Campbell — 2005
• Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylureaA Baksi, Rachel James, Baoan Zhou — 2004
• Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patientsAnthony Barnett, P. J. Grant, G. A. Hitman — 2003
• An International Study of the Effects of Rosiglitazone plus Sulphonylurea in Patients with Type 2 DiabetesVaraphon Vongthavaravat, B L Wajchenberg, Jorge Waitman — 2002
• Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or CXiangjia Zhu, Chunshen Pan, Guangling Li — 2003
• Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.Zsuzsa Kerényi, Holger Samer, Rachel James — 2004
• Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocolP. D. Home, SJ Pocock, Henning Beck‐Nielsen — 2005
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.Steven E. Kahn, Steven M. Haffner, Mark Heise — 2006
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto.Tom A. Elasy, Marie R. Griffin — 2004
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.Martin St. John Sutton, Marc Rendell, Paresh Dandona — 2002
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.‡ — 2006
• Meta-analysis of rare and adverse event dataAlex J. Sutton, Nicola J. Cooper, Paul C. Lambert — 2002
• Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare eventsMichael J. Bradburn, Jonathan J Deeks, Jesse A. Berlin — 2007
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.Lawrence S. Phillips, George Grunberger, Elizabeth R. Miller — 2001
• Medical significance of peroxisome proliferator-activated receptors.Jòseph Vamecq, Norbert Latruffe — 1999
• The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.Craig A. Lygate — 2003

Cited by

• Disorders of body fat distribution in HIV-1-infected patients.Santiago Moreno, Celia Miralles, Eugènia Negredo — 2009
• Discovery and characterization of inflammation-induced electrophilic fatty acid derivativesAlison L. Groeger — 2009
• The Impact of Diabetes and Associated Cardiometabolic Risk Factors on Members: Strategies for Optimizing OutcomesThomas J. Hoerger, Andrew Ahmann — 2008
• Methods for Benefit and Harm Assessment in Systematic ReviewsCynthia M. Boyd, Sonal Singh, Ravi Varadhan — 2012
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.О. В. Котельникова, Е Ю Дрожжина, O. M. Volpina — 2007
• The Avandia DebateMarkus Bohlin, Yue Lu, Johan Kraft — 2007
• 'Cause I said so...渉 深澤 — 2007
• One size does not fit all: the need for a continuous measure for glycemic control in diabetes.David C. Aron, Leonard Pogach — 2007
• Rosiglitazone and heart failure: the controversy and clinical implications.Imran S. Virk, Rubinder S. Ruby, David Tepper — 2007
• Rosiglitazone: A Thunderstorm from Scarce and Fragile DataAugusto Roa Bastos — 2007
• A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.Carl S. Ewig, G. C. Nieman — 2008
• Potential for peroxisome proliferator-activated receptor-γ agonists in progression: beyond metabolismChenyang Lu — 2008
• Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers誠一 鶴田 — 2008
• Sirtuins — novel therapeutic targets to treat age-associated diseasesFrédéric Manns — 2008
• Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.Allen W. Wood — 2008
• Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.João Paulo Vagarinho — 2009
• Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.Stephen Corones — 2009
• Alpha-glucosidase inhibitors in the early treatment of type 2 diabetesV.T. Zaviantseff — 2008
• Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery diseaseСемёнова Ольга Леонидовна — 2009
• Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosisS. Barefoot, Jo Ann — 2009

Related papers

• Clinical Analysis on 40 Cases of Painless Myocardial InfarctionLU Honghua — 2008
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.Mirja Tiikkainen, Anna‐Maija Häkkinen, Elena Korsheninnikova — 2004
• Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle.Sarah J. Lessard, Sonia L. Lo Giudice, Winnie Lau — 2004
• Effect of Rosiglitazone on the Serum Level of Visfatin and Ghrelin in Patients with Type 2 DiabetesLin Meng — 2012
• Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.Martin Muurling, Ronald P. Mensink, Hanno Pijl — 2003
• Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.Ké Li, Ling Li, Mengliu Yang — 2009
• Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone.Daniel Kamin, Colleen Hadigan, Michael Lehrke — 2005
• Evidence for a potent antiinflammatory effect of rosiglitazone.Priya Mohanty, Ahmad Aljada, Husam Ghanim — 2004
• Effects of rosiglitazone on myocardial ultrastructure and atrial natriuretic factor mRNA expression in streptozocin-induced diabetic ratsWanling Wu — 2007